Source | us.nlm.vsac#0.11.0:null (v4.0.1) |
resourceType | ValueSet |
id | 2.16.840.1.113883.3.3616.200.110.102.10002 |
canonical | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3616.200.110.102.10002 |
version | 20221206 |
status | active |
publisher | Clinical Architecture |
name | SARSCoV2VaccinesBivalent |
title | SARS CoV 2 Vaccines, Bivalent |
date | 2023-06-21T18:16:37-04:00 |
experimental | false |
Usages |
|
This value set contains 3 concepts
Code | System | Display |
229 | http://hl7.org/fhir/sid/cvx | SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, bivalent, preservative free, 50 mcg/0.5 mL or 25 mcg/0.25 mL dose |
300 | http://hl7.org/fhir/sid/cvx | SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, bivalent, preservative free, 30 mcg/0.3 mL dose, tris-sucrose formulation |
301 | http://hl7.org/fhir/sid/cvx | SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, bivalent, preservative free, 10 mcg/0.2 mL dose, tris-sucrose formulation |
Produced 08 Sep 2023